Summary for Clinicians: Clinical Practice Guideline for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations
Hossain et al offer a clinical practice guideline for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). An evidence-based guideline for the treatment of patients with SSc-ILD was created in 2023 by a panel of multidisciplinary experts. Systematic literature reviews...
Gespeichert in:
Veröffentlicht in: | Annals of the American Thoracic Society 2024-01, Vol.21 (1), p.12-16 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Hossain et al offer a clinical practice guideline for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). An evidence-based guideline for the treatment of patients with SSc-ILD was created in 2023 by a panel of multidisciplinary experts. Systematic literature reviews were performed for the following therapies: cyclophosphamide, mycophenolate, rituximab, tocilizumab, nintedanib, combination of nintedanib plus mycophenolate, pirfenidone, and combination of pirfenidone plus mycophenolate. Interstitial lung disease frequently complicates SSc, resulting in increased morbidity and mortality. SSc-ILD is the most common cause of SSc-related death. |
---|---|
ISSN: | 2329-6933 2325-6621 |
DOI: | 10.1513/AnnalsATS.202309-760CME |